• Diarrhea

Zinplava Generic Name & Formulations

General Description

Bezlotoxumab 25mg/mL; soln for IV infusion after dilution; preservative-free.

Pharmacological Class

Human IgG1 monoclonal antibody.

How Supplied

Single-dose vial (40mL)—1


Generic Availability


Mechanism of Action

Bezlotoxumab, a human monoclonal antibody, inhibits the binding of toxin B and prevents its effects on mammalian cells. Bezlotoxumab does not bind to C. difficile toxin A.

Zinplava Indications


To reduce recurrence of Clostridioides difficile infection (CDI) in patients who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.

Limitations of Use

Not for treating CDI. Use only in conjunction with antibacterial drug treatment of CDI.

Zinplava Dosage and Administration

Adults and Children

<1yr: not established. Infuse over 60mins. ≥1yr: a single dose of 10mg/kg.

Zinplava Contraindications

Not Applicable

Zinplava Boxed Warnings

Not Applicable

Zinplava Warnings/Precautions


History of CHF. Pregnancy. Nursing mothers.

Zinplava Pharmacokinetics


  • Mean volume of distribution: 7.33 L.


  • Half-life: ~19 days. Geometric mean clearance: 0.317 L/day.

Zinplava Interactions

Not Applicable

Zinplava Adverse Reactions

Adverse Reactions

Nausea, pyrexia, headache, infusion-related reactions; heart failure.

Zinplava Clinical Trials

See Literature

Zinplava Note

Not Applicable

Zinplava Patient Counseling

See Literature